Clinical Trends for March 2016

Ryan Syrek


March 25, 2016

Each week, we identify one top search term, speculate as to what caused its popularity, and provide an infographic on a related condition. If you have thoughts about what’s trending and why, feel free to share them with us on Twitter or Facebook!

Clinical Trend of the Week (March 19-25): HSDD Symptoms

A new study about the efficacy and safety of a high-profile drug is responsible for this week’s top search term. Researchers conducted a systemic review and meta-analysis of randomized clinical trials to assess flibanserin (Addyi), a drug that was approved by the US Food and Drug Administration (FDA) in August 2015 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Sometimes inaccurately referred to as “female Viagra,” the drug was found by the study to only result in, on average, one-half additional satisfying sexual event (SSE) per month, while significantly increasing risk for nausea, fatigue, dizziness, and somnolence. The researchers graded the quality of the evidence as very low and recommended future studies explore various issues before the drug can be routinely recommended in guidelines and clinical practice.

For more information on the causes of female sexual dysfunction, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.